Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07123103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1
SponsorExelixis
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 5 to 9v4
  2. Study sites: 2 to 5v3
  3. Study sites: 1 to 2 Start date changed from estimate of Aug 11, 2025 to Aug 18, 2025v2 Show 1 more changeShow less
    • Start date changed from estimate of Aug 11, 2025 to Aug 18, 2025
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Trial Details
NCT Number NCT07123103
Lead Sponsor Exelixis
Conditions Solid Tumors
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov